Is Phio Pharmaceuticals Corp. (PHIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 42.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 42.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 93.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 42.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 93.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -69.9% | |
| Return on Assets (ROA) | -42.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Current Ratio | 16.0 |
| Total Assets | $21M |
Price & Trading
| Last Close | $1.26 |
| 50-Day MA | $1.13 |
| 200-Day MA | $1.73 |
| Avg Volume | 3.9M |
| Beta | 0.9 |
|
52-Week Range
$0.81
| |
About Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Phio Pharmaceuticals Corp. (PHIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Phio Pharmaceuticals Corp. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Phio Pharmaceuticals Corp.'s debt ratio?
Phio Pharmaceuticals Corp.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Phio Pharmaceuticals Corp.'s key financial metrics?
Phio Pharmaceuticals Corp. has a market capitalization of $15M. Return on equity stands at -69.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.